Anti-inflammatory Effects of Colchicine on Thrombolysis in myocardial infarction (TIMI) flow grade, Myocardial Perfusion Grade (MPG) and no-reflow rate in patients undergoing Primary Percutaneous coronary intervention (PCI) in acute MI phase

Deputy of Research and Technology of Tehran University of Medical Sciences0 个研究点目标入组 320 人开始时间: 待定最近更新: 2018年9月11日

适应症

试验速览

暂无简介。

•Patients who are candidates for the Primary PCI
•Pain or chest discomfort greater than or equal to 20 minutes, less than or equal to 12 hours, and ST elevation = 1 mm in the adjacent limb leads and precordial leads except for V2, V3, or ST elevation = 2 mm in V2, V3 in men or ST height = 1.5 mm in V2, V3 in women.
•Obtain informed consent from all patients before enrollment

•Patients who are only undergoing angiography for diagnostic purposes and do not undergo PCI
•Patients who have been treated with Colchicine due to chronic illness
•Colchicine intolerance history
•Glumerolar filtration Rate less than 30 ml/min and Dialysis patients
•Malignancy and infection
•Oral steroids or NSAIDs ( Except for aspirin) within 72 hours prior to PCI
•Use of CYP 3A4 / P-glycoprotein inhibitor drugs (Ritonavir / Ketoconazole / Clarithromycin / Cyclosporine / Diltiazem / Vrapaemia)
•Patients who suffered cardiac arrest, cardiogenic shock (systolic pressure less than 90), VF, or under CPR in emergency setting
•Start angina more than 12 hours

发起方

Deputy of Research and Technology of Tehran University of Medical Sciences